IceCure Expands ProSense Footprint in Brazil Following FDA Milestone
IceCure Medical is accelerating the commercial rollout of its ProSense cryoablation system across Brazil, buoyed by recent U.S. FDA clearance for early-stage breast cancer treatment. The technology, which destroys tumors through freezing, is gaining traction as a minimally invasive alternative to traditional surgery in major Brazilian medical centers.
The company showcased its latest clinical progress at the SOBRICE Onco 2026 congress, highlighting the technology’s application in treating breast, lung, kidney, and musculoskeletal tumors. IceCure CEO Eyal Shamir noted that the FDA approval has acted as a significant catalyst, heightening awareness among Brazilian clinicians and institutions regarding the system's efficacy.
Clinical adoption is currently supported by high-profile medical experts, including Dr. José Hugo Luz of the Instituto Nacional De Câncer and Dr. Vanessa Sanvido of HCor Hospital. To further validate the technology, Dr. Sanvido is leading a 750-patient study in Brazil, while Dr. Toulsie Ramtohul of France’s Institut Curie is spearheading a separate 900-patient trial. These researchers presented their findings and conducted master classes at the Albert Einstein hospital in São Paulo, marking a strategic push to integrate cryoablation into the national standard of care through partnerships with local distributor KTR Medical.
Comments (0)
No comments yet. Be the first!